Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Background Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation. For people

  • 0 views
  • 22 Mar, 2021
  • 1 location
Encorafenib Plus Binimetinib for People With BRAF V600E Mutated Relapsed/Refractory HCL

Background Hairy cell leukemia (HCL) does not usually respond to chemotherapy. Most people with HCL have a BRAF gene mutation. This can increase the growth of

  • 0 views
  • 20 Mar, 2021
  • 1 location
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early clinical data have demonstrated anti-tumor activity with …

  • 0 views
  • 09 May, 2021
  • 11 locations
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving dabrafenib and trametinib before surgery may make the tumor

neutrophil count
follicle stimulating hormone
trametinib
thromboplastin
BRAF
  • 10 views
  • 12 Apr, 2021
  • 1 location
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

This study is being done to see if adding the study drug, cemiplimab, to the standard therapy with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.

neutrophil count
anaplastic thyroid carcinoma
metastasis
ct scan
cancer
  • 0 views
  • 05 Mar, 2021
  • 7 locations
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

begins in LCH cells (a type of dendritic cell which fights infection). Sometimes there are mutations (changes) in LCH cells as they form. These include mutations of the BRAF gene. These changes may make

  • 4 views
  • 28 Jan, 2021
  • 3 locations
Nivolumab With Trametinib and Dabrafenib or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

This phase II trial studies the side effects and how well nivolumab with trametinib and dabrafenib, or encorafenib and binimetinib work in treating patients with BRAF-mutated stage III-IV melanoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, …

immunomodulators
metastasis
trametinib
ipilimumab
immunologic adjuvant
  • 130 views
  • 13 Apr, 2021
  • 1 location
A Combination of Vemurafenib Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation

. The most common mutation is the substitution of valine for glutamic acid in position 600 of BRAF gene. The influence of this mutation was confirmed by G.Badalyan-Very et al. in 2010. About 64% of all

  • 0 views
  • 24 Jan, 2021
  • 1 location
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab MK-3475

This phase IIa trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with non-small cell lung cancer that has spread to other places in the body or head and neck squamous cell cancer that has come back or spread to other places in the body. …

head and neck carcinoma
neutrophil count
anticoagulants
biomarker analysis
aptt
  • 26 views
  • 23 Jan, 2021
  • 1 location
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

This is a single-centre, open-label Phase II study of the investigational drugs binimetinib and encorafenib that will be taken my mouth (orally) daily in adult patient with advanced and/or metastatic solid tumors for which no other standard therapy is available. The main purpose is to evaluate the objective response rate …

neutrophil count
metastasis
growth factor
measurable disease
BRAF
  • 0 views
  • 24 Jan, 2021
  • 1 location